1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalized Cancer Medicine Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Monoclonal Antibodies
1.2.3 Personalized Cancer Vaccines
1.2.4 Other
1.3 Market by Application
1.3.1 Global Personalized Cancer Medicine Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Chronic Myeloid Leukaemia
1.3.5 Bowel Cancer
1.3.6 Other Cancer
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Personalized Cancer Medicine Market Perspective (2017-2028)
2.2 Personalized Cancer Medicine Growth Trends by Region
2.2.1 Personalized Cancer Medicine Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Personalized Cancer Medicine Historic Market Size by Region (2017-2022)
2.2.3 Personalized Cancer Medicine Forecasted Market Size by Region (2023-2028)
2.3 Personalized Cancer Medicine Market Dynamics
2.3.1 Personalized Cancer Medicine Industry Trends
2.3.2 Personalized Cancer Medicine Market Drivers
2.3.3 Personalized Cancer Medicine Market Challenges
2.3.4 Personalized Cancer Medicine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Personalized Cancer Medicine Players by Revenue
3.1.1 Global Top Personalized Cancer Medicine Players by Revenue (2017-2022)
3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Players (2017-2022)
3.2 Global Personalized Cancer Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Personalized Cancer Medicine Revenue
3.4 Global Personalized Cancer Medicine Market Concentration Ratio
3.4.1 Global Personalized Cancer Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Cancer Medicine Revenue in 2021
3.5 Personalized Cancer Medicine Key Players Head office and Area Served
3.6 Key Players Personalized Cancer Medicine Product Solution and Service
3.7 Date of Enter into Personalized Cancer Medicine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Personalized Cancer Medicine Breakdown Data by Type
4.1 Global Personalized Cancer Medicine Historic Market Size by Type (2017-2022)
4.2 Global Personalized Cancer Medicine Forecasted Market Size by Type (2023-2028)
5 Personalized Cancer Medicine Breakdown Data by Application
5.1 Global Personalized Cancer Medicine Historic Market Size by Application (2017-2022)
5.2 Global Personalized Cancer Medicine Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Personalized Cancer Medicine Market Size (2017-2028)
6.2 North America Personalized Cancer Medicine Market Size by Country (2017-2022)
6.3 North America Personalized Cancer Medicine Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Personalized Cancer Medicine Market Size (2017-2028)
7.2 Europe Personalized Cancer Medicine Market Size by Country (2017-2022)
7.3 Europe Personalized Cancer Medicine Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Personalized Cancer Medicine Market Size (2017-2028)
8.2 Asia-Pacific Personalized Cancer Medicine Market Size by Country (2017-2022)
8.3 Asia-Pacific Personalized Cancer Medicine Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Personalized Cancer Medicine Market Size (2017-2028)
9.2 Latin America Personalized Cancer Medicine Market Size by Country (2017-2022)
9.3 Latin America Personalized Cancer Medicine Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Personalized Cancer Medicine Market Size (2017-2028)
10.2 Middle East & Africa Personalized Cancer Medicine Market Size by Country (2017-2022)
10.3 Middle East & Africa Personalized Cancer Medicine Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott Personalized Cancer Medicine Introduction
11.1.4 Abbott Revenue in Personalized Cancer Medicine Business (2017-2022)
11.1.5 Abbott Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Personalized Cancer Medicine Introduction
11.2.4 Merck Revenue in Personalized Cancer Medicine Business (2017-2022)
11.2.5 Merck Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Personalized Cancer Medicine Introduction
11.3.4 Novartis Revenue in Personalized Cancer Medicine Business (2017-2022)
11.3.5 Novartis Recent Development
11.4 Amgen
11.4.1 Amgen Company Detail
11.4.2 Amgen Business Overview
11.4.3 Amgen Personalized Cancer Medicine Introduction
11.4.4 Amgen Revenue in Personalized Cancer Medicine Business (2017-2022)
11.4.5 Amgen Recent Development
11.5 Celgene
11.5.1 Celgene Company Detail
11.5.2 Celgene Business Overview
11.5.3 Celgene Personalized Cancer Medicine Introduction
11.5.4 Celgene Revenue in Personalized Cancer Medicine Business (2017-2022)
11.5.5 Celgene Recent Development
11.6 Bayer
11.6.1 Bayer Company Detail
11.6.2 Bayer Business Overview
11.6.3 Bayer Personalized Cancer Medicine Introduction
11.6.4 Bayer Revenue in Personalized Cancer Medicine Business (2017-2022)
11.6.5 Bayer Recent Development
11.7 Roche
11.7.1 Roche Company Detail
11.7.2 Roche Business Overview
11.7.3 Roche Personalized Cancer Medicine Introduction
11.7.4 Roche Revenue in Personalized Cancer Medicine Business (2017-2022)
11.7.5 Roche Recent Development
11.8 Astellas
11.8.1 Astellas Company Detail
11.8.2 Astellas Business Overview
11.8.3 Astellas Personalized Cancer Medicine Introduction
11.8.4 Astellas Revenue in Personalized Cancer Medicine Business (2017-2022)
11.8.5 Astellas Recent Development
11.9 Astrazeneca
11.9.1 Astrazeneca Company Detail
11.9.2 Astrazeneca Business Overview
11.9.3 Astrazeneca Personalized Cancer Medicine Introduction
11.9.4 Astrazeneca Revenue in Personalized Cancer Medicine Business (2017-2022)
11.9.5 Astrazeneca Recent Development
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Detail
11.10.2 Johnson & Johnson Business Overview
11.10.3 Johnson & Johnson Personalized Cancer Medicine Introduction
11.10.4 Johnson & Johnson Revenue in Personalized Cancer Medicine Business (2017-2022)
11.10.5 Johnson & Johnson Recent Development
11.11 Agilent
11.11.1 Agilent Company Detail
11.11.2 Agilent Business Overview
11.11.3 Agilent Personalized Cancer Medicine Introduction
11.11.4 Agilent Revenue in Personalized Cancer Medicine Business (2017-2022)
11.11.5 Agilent Recent Development
11.12 Takeda
11.12.1 Takeda Company Detail
11.12.2 Takeda Business Overview
11.12.3 Takeda Personalized Cancer Medicine Introduction
11.12.4 Takeda Revenue in Personalized Cancer Medicine Business (2017-2022)
11.12.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
